The hepatitis B nucleocapsid protein consists of 2 structurally and functionally separate domains; the sequence from the N-terminus to approximately amino acid position 149 is, by itself, sufficient for assembly, whereas the C-terminus is involved in pregenomic encapsidation. Hepatitis B core antigen (HBcAg) is a major immune target [1, 2] that can function as a T cell-dependent and T cell-independent antigen [3] . Hepatitis B e antigen (HBeAg), on the other hand, is a nonessential secreted variant of the core protein, and it is believed to be an immune modulator that somehow suppresses cytotoxic T lymphocyte (CTL) responses. Once an immune response against HBeAg has developed, it is advantageous for the virus to suppress production of HBeAg. Pathogenicity results from the in-
The hepatitis B nucleocapsid protein consists of 2 structurally and functionally separate domains; the sequence from the N-terminus to approximately amino acid position 149 is, by itself, sufficient for assembly, whereas the C-terminus is involved in pregenomic encapsidation. Hepatitis B core antigen (HBcAg) is a major immune target [1, 2] that can function as a T cell-dependent and T cell-independent antigen [3] . Hepatitis B e antigen (HBeAg), on the other hand, is a nonessential secreted variant of the core protein, and it is believed to be an immune modulator that somehow suppresses cytotoxic T lymphocyte (CTL) responses. Once an immune response against HBeAg has developed, it is advantageous for the virus to suppress production of HBeAg. Pathogenicity results from the in-ability to avoid reinfection of hepatocytes and from the incomplete suppression of replication by T cells. Although HBcAg and HBeAg are serologically distinct, the primary amino acid sequence is identical over a large stretch of amino acid sequences. Three shared binding sites for anti-hepatitis B e (HBe) and antihepatitis B c (HBc) have been mapped to core amino acid positions 74-89, 107-118, and 128-135 of HBcAg (table 1 ). An additional antigenic site has been proposed within the arginine-rich C-terminus domain of HBcAg that, unlike the other epitopes, faces the interior of the nucleocapsid [4] (table 1) . These 2 proteins are also highly cross-reactive at the T helper (Th) and CTL levels. In chronic carriers, seroconversion from HBeAg to anti-HBe can lead to either ongoing, often severe disease or remission of hepatitis. Among patients who experienced seroconversion from HBeAg to anti-HBe, there exists supportive indirect evidence for the proposed immunomodulatory role of HBeAg [12] [13] [14] . In patients whose disease went into remission, mutations tended to cluster in CD4-Th epitopes, whereas, in patients with ongoing disease, mutations clustered in B cell epitopes [15, 16] , although not in CTL epitopes a For all patients in the present study. [9, 17, 18] . Nearly all those selections occurred at the time of, or soon after, emergence of the precore stop codon. One interpretation of this finding is that the loss of HBeAg led to increased immune activity. Samples that were obtained later during the anti-HBe-positive phase, during peaks in hepatic activity, showed few additional changes, and such changes did not occur within epitopes. These and other results have led to a conundrum concerning the pathogenesis of disease in patients who had seroconversion to anti-HBe and went on to have either remission or active-disease phases. If hepatitis B virus (HBV) disease is immune mediated, as is believed, then why should viruses, which appear to have escaped the immune response, still cause disease? One suggestion is that there may be immune targets in other regions of the genome, in which case one might predict that selection would occur sequentially in these other proteins. Alternatively, the mutated viruses may be directly cytopathic or may become novel targets for other relatively unstudied arms of the immune response, such as NK cells [19] [20] [21] . Several histologic studies of the association between expression of HBcAg and liver cell damage have been performed. However, little is known about cellular localization of HBcAg variants. For HBeAg-positive patients [22] [23] [24] [25] [26] and for antiHBe-positive patients whose disease is in remission [24, 27, 28] , staining for HBcAg in liver biopsy specimens tends to be nuclear; however, for anti-HBe-positive patients with ongoing disease [23, [29] [30] [31] [32] , staining tends to be both nuclear and cytoplasmic. This cannot be related only to a high level of replication, because HBeAg-positive patients usually are highly viremic. In vitro, the cellular localization of HBcAg is dependent on the phase of the cell cycle [33] . HBcAg is usually confined to the nucleus when cells are blocked in the G1/S phase. This may explain, in part, the in vivo observations that core protein is expressed more predominantly in the cytoplasm during periods of active disease when liver cells are dividing. Conversely, during periods of clinical remission of disease, when hepatocytes are quiescent, core protein is mainly confined to the nucleus. If sequence could be shown to correlate with distribution of HBcAg-especially if distribution changes with selection of mutations in individual patients-this would provide important clues regarding the potential mechanisms of liver damage.
In the present study, we examined the distribution of HBcAg in transfected cells from samples successively obtained from patients with chronic hepatitis B disease. The distribution of HBcAg was correlated with sequence variation within B cell epitopes and the C-terminus. Next, using mutagenesis, we directly investigated the influence of these mutations with regard to intracellular trafficking.
PATIENTS, MATERIALS, AND METHODS
Patients. All 14 patients who participated in the study were Greek or Italian, had known HBV genotypes, and were under the care of the authors of the present study. The patients were selected for inclusion in the study, on the basis of previous characterization of their sequential HBV precore and core sequences [34] . Twenty-six serum samples were studied and were categorized as belonging to 1 of 3 groups (table 2) . Group 1 comprised all samples obtained from 6 patients. Group 1-A included only the samples that were obtained from these 6 patients when they were HBeAg positive (including 2 initial samples [1A 1 and 1A 2 ] obtained from the first patient). Group 1-B included a second set of samples from the same 6 patients, all of which were obtained after the patients underwent anti-HBe seroconversion. Group 2 included all samples obtained from 5 patients who had active disease and who were found to be continuously antiHBe positive. Group 2-A included the samples obtained from these 5 patients during an early period when few mutations were apparent in HBcAg. Group 2-B included a second set of samples obtained from the same 5 patients after selection of either a precore stop codon and/or у1 HBcAg mutation. Group 3 included all samples obtained, at a single point in time, from HBeAg-positive patients with chronic disease.
Polymerase chain reaction (PCR), cloning, and mutagenesis. DNA was extracted from 50 mL of serum by use a QIAamp blood kit (Qiagen). Nested PCR was performed on 5 mL of extracted DNA, by use of primers to the core region of HBV, as described elsewhere [15] . One microliter of first-round PCR products was nested using primers that contained the restriction enzyme sites EcoRI and HindIII, respectively. The second-round PCR products were purified using Geneclean (BIO101), according to the manufacturer's instructions. Ten microliters of the products purified using Geneclean were used in a restriction digest with 10 U each of EcoRI and HindIII (Life Technologies), were run on a 1% agarose gel, and were purified using Geneclean. These fragments were ligated into the multiple-cloning site of the eukaryotic expression vector pRK5 (a gift from H. Will, Heinrich-pette-Institute, Hamburg, Germany), which contained a cytomegalovirus promoter. Competent Escherichia coli strain DH5a was transformed with the ligation reactions, colonies were picked, and clones that contained inserts were identified by restriction digests of minipreparations of DNA. Large-scale preparations of DNA for transfection were prepared over 2 CsCl density gradients. The constructs were sequenced to confirm the presence of mutations.
Site-directed mutagenesis was performed with a PCR method that used oligonucleotides to revert mutated sequences back to the wild-type sequence (according to original sequences in the early phase and/or normal variations in the corresponding genotype, as obtained from a database), according to the manufacturer's instructions (Stratagene). Sequencing of the plasmid confirmed the presence of mutations. All relevant sequence information is found in table 3. Cell culture, transfection, and immunofluorescence. It is known that the distribution of expressed HBcAg is cell cycle dependent. Sequential thymidine-and aphidicolin-blocking steps Table 3 .
In vitro mutation of cytoplasmically distributed sequences.
Mutated virus
Mutagenesis position a HBcAg localization B cell epitope
Confocal microscopy was used to study the distribution of hepatitis B core antigen (HBcAg) after mutation was confirmed by sequencing. C, Predominantly cytoplasmic distribution; HBc-1, hepatitis B core 1st B cell epitope; HBc-2, hepatitis B core 2nd B cell epitope; N, predominantly nuclear distribution; NC, mixed nuclear and cytoplasmic localization; +, 25% of stained cells; ++, 50% of stained cells; +++, 75% of stained cells.
a The mutations generated are listed according to their amino acid position within an epitope. Letters appearing before each no. denote the mutated sequence to wild type, and letters appearing after each no. denote the original sequence before mutagenesis. produced monolayers of synchronized Cos-7 cells (data not shown). Twelve hours before treatment with cell cycle-blocking agents, Cos-7 cells were seeded at a density of 3 ϫ 10 4 cells/well, in a 24-well plate, in growth medium. Medium that contained 2 mmol/L thymidine replaced the aforementioned medium, and, 12 h later, cells were washed twice with PBS and overlayed with normal medium. Transfections were done after thymidine withdrawal and cell release, by use of FuGENE-6 and/or Lipofectamine Plus transfection reagent (Invitrogen), according to the manufacturer's instructions. After an additional 13 h, the cells were washed twice with PBS, medium that contained 2.5 mg/mL aphidicolin was added, and the cells then were incubated for an additional 36 h. Aphidicolin blocks cells in the G1/S phase of the cell cycle, in which expression of HBcAg is predominantly nuclear [23] . This inhibits movement of HBcAg into the cytoplasm because of dissolution of the nuclear membrane, implying that any cytoplasmic expression is more likely to be the result of active transport.
FACS analysis. The cell-cycle status of cultured cells was determined by flow cytometric analysis of permeabilized cells that were stained with propidium iodide. Cos-7 cells were dissociated with EDTA at the appropriate time after transfection and were resuspended in PBS. Cells underwent centrifugation at 1500 g for 2 min and then were fixed with 70% ethanol on ice. After 20 min, the cells underwent centrifugation, were washed once with PBS, and then underwent centrifugation again. Pelleted cells were resuspended in 1 mL of a solution that contained 0.5% Triton X-100, propidium iodide, and RNase. After incubation for 30 min at room temperature, the total DNA content was analyzed in the FL3-H channel of a FACS flow cytometer (Beckton Dickinson).
Immunofluorescence and confocal microscopy. Localization of core protein was studied using immunofluorescence and confocal microscopy. Cells were fixed with ice-cold methanol. After permeabilization with 0.5% Triton X-100, rabbit anti-core polyclonal Ig G (Zymed) and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (Sigma) were used as primary and secondary antibodies, respectively. Then, cell samples were examined using a Zeiss LSM510 confocal microscope with laser excitation at 488 nm. The intracellular distribution and quantitative expression of HBcAg were determined by random evaluation of у100 cells with either a 40ϫ or a 63ϫ oilimmersion objective lens. Cells had either predominantly nuclear distribution or predominantly cytoplasmic distribution if 170%-80% of cells showed nuclear or cytoplasmic HBcAg, respectively. If a similar proportion of cells expressed HBcAg in both the nucleus and the cytoplasm, they were considered to have nuclear and cytoplasmic localization. Data sets were processed using LSM510 software (Zeiss).
RESULTS

Synchronization of Cos-7 Cells by Thymidine-Aphidicolin
To study the influence of the cell cycle on the subcellular distribution of HBcAg, Cos-7 cells were synchronized by the use of 2 blocking agents. In initial experiments (data not shown), aphidicolin, when used alone soon after transfection, yielded poor transfection efficiencies. Consequently, a 2-step cell-cycle synchronization was used. As a first step, cells were incubated in the presence of thymidine for 12 h, to enter the G0/G1 phase of the cell cycle (figure 1B). Afterward, cells were withdrawn from thymidine and were permitted to progress out of the G0/ G1 phase and into the S, G2, and then M phases of the cell cycle for 12 h ( figure 1C) . After cell-cycle release, the cells were washed twice with PBS, and transfection was done using FuGENE-6 and/ or Lipofectamin Plus transfection reagent methods. As a second step, 12 h after transfection, the cells were treated with 2.5 mg/ mL aphidicolin for 30 h. Synchronization achieved by use of aphidicolin resulted in 94% of the cells remaining in the G1/ S phase ( figure 1D and 1E) . 
Distribution of Mutations in the Core Gene B Cell Epitopes and the C-Terminus Region
Overall, 34 mutations were distributed in different known B cell epitope regions within the core gene (table 1) . Twenty-two mutations (64%) occurred in amino acid residues 74-89, whereas 3 mutations (9%) occurred in amino acid residues 107-118 and 9 mutations (26%) occurred in amino acid residues 128-135 (table 4). Of 22 mutations in the first B cell epitope (amino acid residues 74-89), 8 mutations occurred at amino acid position 80. Thirteen (59%) of 22 C-terminus mutations occurred within amino acid residues 148-160 (table 4) .
Cellular Distribution of Core Protein
Expression of HBcAg was predominantly nuclear in 13 samples, both nuclear and cytoplasmic in 3 samples, and predominantly cytoplasmic in 10 samples. Of the 13 samples that showed pre-dominantly nuclear expression of HBcAg, 9 were HBeAg positive and 4 were anti-HBe positive (i.e., samples 8A, 9A, 11A, and 10B; note that 3 of the samples that showed nuclear expression were initial samples) (see below). Only 1 patient whose sample (sample 1A 1 ) showed a predominantly cytoplasmic distribution of HBcAg was HBeAg positive; in other words, 9 patients were anti-HBe positive. In keeping with this finding, none of the patients whose samples had both nuclear and cytoplasmic distribution of HBcAg were HBeAg positive; in other words, all of these patients were anti-HBe positive. Also, we observed a form of nuclear expression associated with the membrane, by use of standard microscopy (results not shown). Figure 2 and tables 2 and 4 detail the patterns of core localization in 4 patient-derived HBV core genes cloned into pRK5 and transfected into G0/1-arrested Cos-7 cells. Consequently, the first finding of the present study is that cytoplasmic distribution of HBcAg is closely associated with HBeAg negativity/anti-HBe positivity.
Core gene sequences from the initial samples showed nuclear distribution. Tables 2 and 4 show the results of core gene substitutions in 12 initial samples (either HBeAg-positive or anti-HBe-positive samples) and in 3 HBeAg-positive samples obtained at a single point in time. Twelve of these 15 samples showed predominantly nuclear distribution (only 1 of the samples obtained later during the anti-HBe-positive phase [sample 10B] had nuclear localization; a total of 13 samples had predominantly nuclear localization). Eight of 13 samples (all but 1 of which were from HBeAg-positive patients) did not have any mutation. The remaining 5 samples (3 of which were anti-HBe positive) had mutations in either the C-terminal region and/or the B cell epitopes. Two of these samples (samples 9A and 5A) had mutations only in B cell epitopes (A74V/G [2 possible variants for genotype D] and T80A, respectively). An additional 2 samples contained mutations in both regions; sample 6A showed mutations T80A, Q130P, C153G, and T155S, and sample 11A showed mutations S135P, Q151R, and T155S. Only 1 sample (sample 8A) with a C-terminus mutation alone (C153G) was observed. As noted in the next subsection, a second set of samples that were obtained from the same 5 patients later during the anti-HBe-positive phase developed further mutations and shifted to the cytoplasm. Finally, HBcAg from the remaining 2 initial samples (samples 10A and 7A) showed either predominantly cytoplasmic distribution or both nuclear and cytoplasmic distribution, respectively ( figure 2, sample 10A) . Therefore, all but 2 of the initial samples that were obtained showed predominantly nuclear expression. It was unusual to observe C-terminus and/or B cell epitope mutations and nuclear localization of samples that were HBeAg positive.
Accumulation of B cell epitope/C-terminus mutations and HBcAg localization. For the 5 patients with initial samples that contained B cell epitope and/or C-terminus mutations and predominantly nuclear localization (samples 5A, 6A, 8A, 9A, and 11A) (table 2), there was a shift, over time, both in cellular distribution and sequence. Samples that were obtained later during the anti-HBe-positive phase (samples 5B, 6B, 8B, 9B, and 11B) (table 2) had predominantly cytoplasmic distribution (see below): all sequences in the latter group contained additional mutations in the same and/or other regions (table 4) . Thus, it appears that there is an association between accumulation of additional mutations and a shift to cytoplasmic distribution.
A shift in cellular distribution to the cytoplasm is linked to substitutions in the carboxy terminal and/or B cell epitopes. Of the 10 samples with predominantly cytoplasmic distribution that were obtained later in the study, 8 contained both Cterminus and B cell epitope mutations (tables 2 and 4). Sample 2B contained only a C-terminus mutation (A160T), whereas sample 10A only had mutations in 2 B cell epitopes (A74V/G and P131A). Sample 10B, although obtained later during the anti-HBe-positive phase, shifted back to the nucleus: in keeping with this finding, all the mutations in sample 10A (the first sample obtained) reverted back to the wild type (i.e., there were no mutations) in sample 10B (figure 2 and table 4). Sample 8A, which was obtained during the initial phase and which had a C-terminus mutation (C153G) (see above), reverted back, and an L156P mutation arose during the anti-HBe-positive phase (table 4, sample 8B). An additional amino acid variation (G74V) occurred in the sample obtained during the later phase (sample 8B). Both of these variants in amino acid position 74 are specific for genotype D [35] . Both the samples that showed nuclear and cytoplasmic distribution (samples 7B and 9B) contained mutations in both the C-terminus and the B cell epitope regions (table 4). In sequences with mutations, there were no differences in the distribution of those mutations between the 2 clinical groups (i.e., patients with seroconversion from HBeAg to anti-HBe and patients who were continuously anti-HBe positive). Thus, all samples obtained during the later phase showed predominantly cytoplasmic distribution (including both nuclear and cytoplasmic distribution) and contained B cell epitope and/ or C-terminus mutations. All but 1 of the samples were antiHBe positive. As a result, cytoplasmic distribution of HBcAg was strongly correlated with the presence of mutations in B cell epitopes and/or the C-terminus region of the C gene as well as with anti-HBe positive status.
Correlation of HBcAg Localization with Clinical Outcome
Of the 11 samples obtained during the later phase, 4 were obtained from patients whose disease was in clinical remission and 7 were obtained from patients who had active disease. Samples from the 4 patients whose disease was in clinical remission showed a shift in the distribution of HBcAg from the nucleus to the cytoplasm after seroconversion to anti-HBe. All but 1 of the samples (sample 10B) from the 7 patients who had active disease showed a shift from nuclear to cytoplasmic expression, 
NOTE. B cell and T helper epitopes and C-terminus areas, with their boundaries and wild-type variants. C, predominantly cytoplasmic distribution; N, predominantly nuclear distribution; NC, mixed nuclear and cytoplasmic localization.
a Amino acids are denoted by a single-letter code and are numbered from the beginning of HBcAg. Only positions at which changes occurred are shown, so the relative proportion of epitopic to nonepitopic areas is skewed in favor of regions where substitutions occurred. b Status of 11 samples obtained from patients who were anti-hepatitis B e positive during a later phase of the study, according to whether the samples were obtained during the remission phase or the active-disease phase.
in a comparison of samples obtained during the earlier and later phases (table 2) . Of interest, with the exception of sample 10B, all samples obtained during the active-disease phase and the remission phase contained B cell epitope and/or C-terminus mutations. Consequently, in 10 of 11 samples obtained later during the study, either from patients with active disease or from patients whose disease was in remission, there was a shift from predominantly nuclear to predominantly cytoplasmic distribution, a finding that indicates that there was no clear difference between different clinical outcomes and HBcAg localization.
Cellular Distribution of the Core Protein is Dependent on the Sequence
Some of the samples that shifted from the nucleus to the cytoplasm in the later phase (table 2) were chosen for site-directed mutagenesis (table 3) . Samples 3B, 4B, and 5B had double mutagenesis, at the same time, on both the C-terminus and B cell epitopes. Because sample 10A did not contain a C-terminus mutation but contained mutations in 2 different B cell epitopes (table 4) , it was selected for double mutagenesis on these epitopes. All experiments were designed to revert the mutated amino acid to the expected amino acid variant for each genotype, which was also that observed in the first sample of the pair obtained (or the second sample, as in the case of patient 10). All clones were sequenced to confirm reversion. After the sequence in the C-terminal and/or B cell epitopes of the later sample was reverted back to the original sequence, a shift back to the original nuclear distribution and/or both nuclear and cytoplasmic distribution was observed. After single amino acids in B cell epitopes underwent mutation, 4 of 5 samples shifted back partially (i.e., they localized to both the nucleus and the cytoplasm) ( figure 2, sample 11B) . In contrast, mutagenesis of C-terminus mutations resulted in predominantly nuclear localization in all cases (figure 2, samples 4B and 5B; table 3). In keeping with these findings, all double-mutated samples shifted back to either nuclear distribution (results not shown) or nuclear and cytoplasmic distribution ( figure 2, sample 10B) . Consequently, reversion of C-terminus mutations leads to shifting of HBcAg back to the nucleus. Reversion of B cell epitope mutations leads to a mixed nuclear and cytoplasmic distribu- 
tion. The effect of dual mutations is the same as that of Cterminus mutations.
Precore Variants
The precore stop codon mutation was found at amino acid position 28 of the precore region in 8 of 13 samples with predominantly cytoplasmic localization; it was found in 4 of 13 samples with predominantly nuclear distribution. Consequently, the precore region did not appear to influence the effect of C gene localization. Note that the pre-C region was not within the cloned product (table 2) , so it did not directly affect localization.
DISCUSSION
The entire HBV genome is extremely stable in the early highreplicative HBeAg-positive phase, when the immune response is considered to be weak [36] . However, after seroconversion of HBeAg to anti-HBe, multiple clusters of mutations appear in different regions of HBcAg-in particular, in immunodominant epitopes (table 1) . Several studies have shown that the amino acid variability of HBcAg is related to the severity of liver disease, both in the HBeAg and the anti-HBe phases [9, 14, 15, 17, 34, 37] . Previous studies have reported HBcAg distribution in the cytoplasm, nucleus, or both, of infected or transfected cells [23-26, 28-30, 32, 37-41] , but none of the studies evaluated naturally mutated sequences. Recently, Kawai et al. [42] found that hepatocytes that exhibited cytoplasmic expression of HBcAg contained more core promoter double mutations (T1762 and A1764) than did hepatocytes that exhibited nuclear expression. Studies of liver biopsy specimens have suggested that the intracellular distribution of HBcAg correlates with disease activity, with cytoplasmic expression being associated with more severe disease [23, 25, 31, 41, 43] . The cell membrane of HBV-infected hepatocytes may also express HBcAg during chronic infection [1, 44] . However, whether intracellular distribution of HBcAg is associated with liver damage is unclear. Previous studies have evaluated biopsy specimens for which the additional influence of host factors has made it difficult to delineate the mechanisms responsible for intracellular distribution of HBcAg. The present study has confirmed previous observations that there is a close association between the topographic distribution of HBcAg in vitro and the inflammatory status of the liver in vivo ( figure 2 and table 2 ). For the first time, it has been shown that the distribution of expressed HBcAg is strongly associated with the viral sequence (tables 2 and 4). The presence of cytoplasmic expression of HBcAg correlated with the existence of mutations in the B cell epitopes and/or the carboxy terminus of the protein. These experiments were performed in the presence of aphidicolin, to block cells in the G1/S phase; consequently, any shift to cytoplasmic expression of HBcAg was not a result of dissolution of the nuclear membrane. However, to prove that sequence was critical in HBcAg localization, reversion of C-terminus and/or B cell epitope mutations back to the wild type was performed; in most cases, reversion shifted HBcAg localization back to the nucleus (table 3) . Some possible explanations for this shifting are presented below.
Machida and et al. [4, 45] reported an antigenic site within the C-terminus region, known as "HBicAg" (hepatitis B inner cAg; amino acid residues 148-160), to be a potential B cell antigenic determinant [39] . In the present study, 13 of 22 Cterminus mutations occurred within amino acid residues 148-160 (table 4) . If the arginine-rich C-terminus is a B cell epitope, that might explain the mutations that occurred in this region. Because this region is also known to affect nuclear localization, mutations would explain the shift of HBcAg to the cytoplasm. This is in line with observations that escape mutations appeared in the B cell epitopes of patients with ongoing disease [15] (tables 2 and 4), because double mutagenesis of both a B cell epitope and C-terminus residue resulted in samples shifting back to both nuclear and cytoplasmic distribution and/or predominantly nuclear distribution (results not shown).
Although B cell epitope mutations tended to shift HBcAg to the cytoplasm, they were not as effective as C-terminus mutations, which probably direct HBcAg intracellular trafficking by a different mechanism(s). A majority of samples with B cell mutagenesis had localization in both the nucleus and the cytoplasm ( figure 2, sample 11B) , whereas all samples with Cterminus mutations showed predominantly nuclear distribution ( figure 2, samples 4B and 5B). This was also observed in 2 of 3 samples with double mutations ( figure 2, sample 10B) . The reason underlying this phenomenon is unclear and deserves more investigation.
In the present study, we clearly showed that, in samples with both nuclear and cytoplasmic localization, HBcAg could be associated with the nuclear membrane (results not shown). This unusual pattern has been reported elsewhere [46] . Because there is no sharp boundary between the G1 and S phases, transport of HBcAg to the nuclear membrane may occur during the transition between phases. It may be that nuclear and/or cytoplasmic localization may be a transition step between the 2 compartments [19] . Alternatively, there may have been high levels of nuclear HBV DNA with inefficient transportation from the nucleus. However, there is no strict division between predominantly nuclear and predominantly cytoplasmic localizations of core protein in vivo, because core particles usually are present in both compartments [32, 37] .
For a majority of patients, a predominantly cytoplasmic distribution in vitro was found in samples obtained during the active-disease phase and the remission phase (table 2). These samples (samples 1A 1 , 1A 2 , 2B, and 3B) selected more mutations in Th epitopes than in the C-terminus region and/or B cell epitopes (table 4) . Of the samples obtained from 7 patients who had active disease, 6 showed a shift from nuclear to cytoplasmic expression in a comparison of samples obtained in the early and later phases (table 2); of these 6 samples, 4 (samples 4B, 6B, 8B, and 11B) had a higher proportion of mutations in B cell epitopes than in other regions (table 4). All samples with active disease were anti-HBe positive; 4 had predominantly nuclear distribution (see above). In keeping with this finding, all 4 samples that had predominantly nuclear localization and were obtained from patients who were continuously anti-HBe positive were obtained from patients with active disease. The only apparent correlation of HBcAg sequences in samples 8A, 9A, 10B, and 11A with those in samples from other anti-HBepositive patients with predominantly cytoplasmic distribution was that fewer mutations were found in these samples, compared with later samples with predominantly cytoplasmic expression (table 4) . Although this unusual expression has been reported elsewhere [42, 46, 47] , it is likely that, after seroconversion of HBeAg to anti-HBe, there is coexistence of both antigen and antibody for some time [48] , with concurrent persistence of a low concentration of integrated HBV DNA in the liver after the disappearance of HBeAg [46] . Nevertheless, continued liver disease activity after seroconversion to anti-HBe status has been reported in certain patients and might be related to continued viral replication and secretion with the presence of HBcAg in the nucleus [22] .
In summary, we have shown that subcellular expression of HBcAg is related to serologic patterns and that it depends on the HBcAg sequence, even in samples successively obtained from individual patients. C-terminus and/or B cell epitope mutations are involved in the shifting of HBcAg between the nucleus and the cytoplasm. These results were generated by transfection. Because there is no susceptible cell line that can be truly infected by HBV, the biological importance of such variants, with regard to the viral life cycle and cell behavior, is still unclear.
